Piper Sandler analyst Edward Tenthoff downgraded Jounce Therapeutics to Neutral from Overweight after Concentra Biosciences agreed to acquire Jounce for $1.85 in cash per share plus a non-tradeable contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNCE:
- Buyout Offer Sends Jounce Jumping 20%
- Jounce Therapeutics Enters Into Agreement to Be Acquired by Concentra Biosciences for $1.85 in Cash per Share Plus Contingent Value Rights
- Jounce Therapeutics implements workforce reduction of 84% of employees
- Jounce to be acquired by Concentra for $1.85 in cash per share plus CVR
- Jounce: Patients from ovarian cancer combo cohort study had durable responses